Clinical Trial Categories
Lung Trials
Trial ID ESR 22-21698 (EIMPRIS)
NCT05438498clinicaltrials.gov ID
Phase II/III
Trial ID 20412
NCT04819100clinicaltrials.gov ID
USOR ID: 20412
Phase III
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)
Trial ID 21318
NCT05170204clinicaltrials.gov ID
USOR ID: 21318
Phase III
A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER
Trial ID 21239
NCT04988295clinicaltrials.gov ID
USOR ID: 21239
Phase III
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
Trial ID
NCT03520686clinicaltrials.gov ID
Phase III
Trial ID 21541
NCT05215340clinicaltrials.gov ID
USOR ID: 21541
Phase III
Tropion-Lung08: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
Trial ID 21320
NCT04486833clinicaltrials.gov ID
USOR ID: 21320
Phase I/II
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib
Trial ID 20422
USOR ID: 20422
Phase N/A
KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials
Trial ID
NCT03175224clinicaltrials.gov ID
Phase I/II
Trial ID 20266
NCT04485013clinicaltrials.gov ID
USOR ID: 20266
Phase Ib
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies
Trial ID 19151
NCT03785249clinicaltrials.gov ID
USOR ID: 19151
Phase II
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Trial ID 20270
NCT04613596clinicaltrials.gov ID
USOR ID: 20270
Phase II
A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Trial ID 21219
NCT05054725clinicaltrials.gov ID
USOR ID: 21219
Phase II
RMC-4630-03: A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Trial ID 19151
NCT03785249clinicaltrials.gov ID
USOR ID: 19151
Phase II
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Trial ID 20331
NCT04620330clinicaltrials.gov ID
USOR ID: 20331
Phase II
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer
Trial ID 20423
NCT04622007clinicaltrials.gov ID
USOR ID: 20423
Phase II
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy
Trial ID
NCT04589845clinicaltrials.gov ID
Phase II
Trial ID 20249
NCT04538664clinicaltrials.gov ID
USOR ID: 20249
Phase III
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cance
Trial ID 20289
NCT04254107clinicaltrials.gov ID
USOR ID: 20289
Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies
